4 products found
Aerami Therapeutics Holdings, Inc. Products
-
Aerami - Inhalation Therapies Technology
Why Inhaled Therapies: Delivery of therapeutics directly to the lungs allows for more precise doses of drugs to achieve therapeutic benefit and avoid adverse events seen with orals and injectables. For a number of cardiopulmonary and cardiometabolic conditions, treatment via inhalation is an ideal alternative to routine injections allowing for improved drug bioavailability and efficacy while providing a better patient ...
-
Model AER-501 - Inhaled Human Insulin for Type 1 and 2 Diabetes
We developed a soft mist inhaled human insulin for the treatment of Type 1 and 2 diabetes. Clinical data based on our five Phase 1/2a studies demonstrated AER-501 has: Faster onset and similar profile when compared to lispro. Intra and inter-subject variability similar to injections. Minimal to no cough following inhalation. These clinical studies also demonstrated the AFINA drop dispenser enables fast, accurate and precise dose loading at a low cost with ...
-
Model AER-601 - Inhaled Glucagon-like Peptide-1 (GLP-1) Analog
We have completed toxicology studies for AER-601. The product candidate is ready to advance into Phase 1 studies. AER-601 is delivered via our AFINA smart inhaler to help individuals with type 2 diabetes (T2D) achieve a superior level of postprandial glucose control and avoid undesirable gastrointestinal side effects associated with injectable ...
-
Model AER-901 - Pulmonary Arterial Hypertension
Inhaled Imatinib for PAH: We have advanced inhaled imatinib, AER-901, into the clinic for the treatment of patients with pulmonary arterial hypertension (PAH). The Phase 1 trial is currently ...